問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

Division of Radiology

更新時間：2023-09-19

林偉雄
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

20Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林偉雄

List

28Cases

2023-09-01 - 2031-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2023-12-01 - 2027-03-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting3Sites

2024-09-01 - 2032-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2024-11-01 - 2029-08-31

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2024-11-01 - 2029-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2025-05-01 - 2028-07-31

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-06-30 - 2032-05-01

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2026-01-15 - 2031-03-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting6Sites

2026-03-04 - 2034-03-11

Phase II/III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2025-09-10 - 2028-06-13

Phase I

Completed
A Phase Ib/III Randomized, Multicenter, Global Study of Volrustomig Plus Casdatifan or Volrustomig Monotherapy Versus Nivolumab Plus Ipilimumab as First-line Treatment for Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

  • Condition/Disease

    Advanced Clear Cell Renal Cell Carcinoma

  • Test Drug

    凍晶注射劑 膜衣錠

Participate Sites
4Sites

Recruiting4Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB